Pharmaceutical major Lupin has plans to establish a manufacturing facility in Coral Springs, Florida, US. The USD 250 million investment, covering research & development, infrastructure, and capital expenditures over five years, will enable the production of more than 25 critical respiratory therapies, including albuterol inhalers for children with asthma and service members in the US and abroad.
The expansion is expected to create over 200 long-term, skilled jobs in Broward County by 2030. The 70,000-square-foot facility will anchor Lupin’s US production of respiratory medicines, diversify the supply chain, and ensure affordable, reliable access—from routine pediatric care to pandemic-scale demand.
Lupin, with its US headquarters in Naples, Florida, operates 15 manufacturing sites and 7 research centres globally and has a presence in over 100 markets, with a strong focus on respiratory care and complex generics.
“The expansion of Lupin’s footprint in Coral Springs is a core part of our growth strategy. This new state-of-the-art facility will build on our existing presence in Florida, which is home to Lupin’s headquarters and our Advanced Inhalation Research Center. This investment demonstrates Lupin’s commitment to innovation, quality and supply chain reliability — and our ability to partner with Florida’s leaders to strengthen America’s medicine security by growing our capacity to produce affordable treatments for patients. We are grateful to Florida’s leadership for their partnership in making this possible,” said Christoph Funke, Chief Technical Operations Officer, Lupin. |
